Results 131 to 140 of about 81,917 (261)

Regulating Lipid Metabolism in Cancer: The Therapeutic Potential of Traditional Chinese Medicine

Phytotherapy Research, EarlyView.
By regulating the reprogramming of lipid metabolism in tumor cells, TCM provides a novel strategy for antitumor therapy with reduced toxicity and enhanced efficacy. ABSTRACT Lipid metabolic reprogramming is a key feature of tumor cells to adapt to the microenvironment and plays an important role in tumor growth, invasion, and metastasis.
Yufeng Gao, Huiming Huang, Xuejiao Wei, Xiaoxue Wang, Wanying Xie, Xinyu Qiu, Fei Wang, Zhuguo Wang, Ruoxin Zhang, Yilin Cai, Changhai Qu, Zhongdong Hu   +11 more
wiley   +1 more source

Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatment. [PDF]

iScience
Rebecca VW, Xiao M, Kossenkov A, Godok T, Brown GS, Fingerman D, Alicea GM, Wei M, Ji H, Portuallo M, Bravo J, Elad V, Chen Y, Toska E, Fane ME, Couts KL, Villanueva J, Nathanson K, Arun KM, Warrier G, Yin X, Ding J, Liu Q, Goyal Y, Gopal YNV, Davies MA, Herlyn M.   +26 more
europepmc   +1 more source

4′‐Hydroxywogonin Attenuates Hepatocellular Carcinoma Progression by Suppressing Gas6/Axl‐PI3K/AKT Signaling

Phytotherapy Research, EarlyView.
4′‐Hydroxywogonin, a flavonoid derived from Scutellaria baicalensis, inhibits hepatocellular carcinoma progression partly by suppressing Gas6/Axl‐PI3K/AKT signaling, inducing cell cycle arrest and apoptosis, and reducing metastatic potential. It also suppresses xenograft tumor growth without evident hepatotoxicity.
Chi‐Yuan Chen, Chin‐Chuan Chen, Chau‐Ting Yeh, Chieh‐Wen Chan, Yu‐De Chu, Yann‐Lii Leu, Roshan B. Satange, Li‐Fang Chou, Wen‐Yu Chuang, Chuen Hsueh, Tzong‐Ming Shieh, Tong‐Hong Wang   +11 more
wiley   +1 more source

The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heart. [PDF]

Sci Adv
Fisher-Wellman KH, Lutze RD, Kirkland LG, Beak JY, Goyal M, Nagalingam R, Morrissey SM, Sandroni PB, Huang W, Bailon JD, Schroder MA, Albrecht LA, Ofei E, Chin AL, Green TD, McClung JM, Montgomery MM, Hagen JT, Chrest BR, Franczak EM, Krassovkaia P, Aruleba RT, Zawistowski JS, Stuhlmiller TJ, Gomez SM, Prathumsap N, Zhang Q, Zhang J, Xu W, Zhang L, Meier JA, Carey LA, Schisler JC, Johnson GL, Jensen BC.   +34 more
europepmc   +1 more source

YTHDF2 in hepatocellular carcinoma: Bridging m6A modification and cancer progression

VIEW, EarlyView.
Abstract YTH N6‐methyladenosine RNAbinding protein F2 (YTHDF2) is an N6‐methyladenosine (m6A) reader protein that mainly regulates the stability of methylated transcripts through mRNA decay. In the liver, YTHDF2 is involved in metabolic homeostasis, oxidative stress responses, and immune regulation.
Sijie Zang, Dongxue Ge, Wanqi Yang, Haobin Shen, Weihong Ge, Li Li, Dayu Chen, Jinglin Wang   +7 more
wiley   +1 more source

Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass. [PDF]

Cancer Res
Kolitz S, Travesa A, Axel A, Funt JM, Nord MS, Yamamura A, Fowler KD, Nair P, Zeskind B, Hall BM, King P.   +10 more
europepmc   +1 more source

MEK inhibitor retinopathy

Annals of Oncology, 2017
openaire   +1 more source

MEK Inhibitor RO4987655 [PDF]

, 2020
openaire   +1 more source

Current Advances of Treatments, Therapeutic Targets, Biomarkers, Novel Drugs, and Machine Learning for Hypopharyngeal Squamous Cell Carcinoma

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Hypopharyngeal squamous cell carcinoma (HSCC) is an aggressive subtype of head and neck squamous cell carcinoma with insidious onset, early metastasis, and dismal prognosis. Conventional multimodal therapy achieves limited survival benefit, highlighting an urgent need for refined precision strategies.
Ce Li, Rui Guan, Rui‐Jie Jiao, Zhi‐Jie Bi, Yang Fu, Yin Wang, Chen‐Yang Xu, Ye Qian, Ran Wei, Sheng‐Da Cao, Wen‐Ming Li, Dong‐Min Wei, Da‐Peng Lei   +12 more
wiley   +1 more source

Repurposing the MEK inhibitor binimetinib as a dual anti-inflammatory and antifibrotic agent in pulmonary fibrosis. [PDF]

J Thorac Dis
Zhang Y, Chen Q, Shi Y, Li Z, Chen R, Wang M, Shao C, Gao S, Zhou H, Huang H.   +9 more
europepmc   +1 more source